A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2018
At a glance
- Drugs CSTC 1 (Primary)
- Indications Alzheimer's disease; Vascular dementia
- Focus Therapeutic Use
- Sponsors Charsire Biotechnology Corporation
- 25 Jul 2018 Last checked against ClinicalTrials.gov record.
- 16 Jul 2018 Planned End Date changed from 31 Dec 2017 to 1 Dec 2021.
- 16 Jul 2018 Planned primary completion date changed from 31 Dec 2017 to 1 Jun 2021.